Edition:
United States

Biospecifics Technologies Corp (BSTC.OQ)

BSTC.OQ on NASDAQ Stock Exchange Global Market

43.83USD
4:00pm EDT
Change (% chg)

$0.74 (+1.72%)
Prev Close
$43.09
Open
$43.13
Day's High
$43.83
Day's Low
$42.89
Volume
7,188
Avg. Vol
8,401
52-wk High
$58.36
52-wk Low
$38.12

Latest Key Developments (Source: Significant Developments)

Biospecifics Technologies Q4 Earnings Per Share $0.36
Wednesday, 14 Mar 2018 08:01am EDT 

March 14 (Reuters) - Biospecifics Technologies Corp ::. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.36.‍TOTAL REVENUE FOR Q4 ENDED DECEMBER 31, 2017 WAS $6.7 MILLION, COMPARED TO $6.6 MILLION FOR SAME PERIOD IN 2016​.  Full Article

Biospecifics Technologies reports Q3 eps of $0.37
Friday, 10 Nov 2017 08:06am EST 

Nov 10 (Reuters) - Biospecifics Technologies Corp ::Biospecifics Technologies Corp reports Q3 2017 financial results.Q3 revenue $6.5 million versus $6.9 million.Q3 earnings per share $0.37.As of september 30, 2017, co had cash & cash equivalents & investments of $61.3 million.  Full Article

Biospecifics Q2 earnings per share $0.35
Tuesday, 9 Aug 2016 04:05pm EDT 

Biospecifics Technologies Corp : Q2 earnings per share $0.35 . Biospecifics technologies corp. Reports second quarter 2016 financial results .Q2 revenue rose 32 percent to $6.2 million.  Full Article

Biospecifics Technologies positive results from phase 2 trial of CCH
Monday, 13 Jun 2016 07:30am EDT 

Biospecifics Technologies Corp : Biospecifics technologies corp. Announces positive top-line results from phase 2 trial of cch for treatment of human lipoma . Trial met its primary endpoint of reduction in visible surface area of target lipomas relative to placebo . There were no serious adverse events reported during trial .Announces Positive Top-Line results from phase 2 trial of cch for treatment of human lipoma.  Full Article

BioSpecifics Technologies Q1 earnings per share $0.39
Tuesday, 10 May 2016 07:53am EDT 

Biospecifics Technologies Corp : Total revenue for Q1 ended march 31, 2016 was $6.6 million , compared to $5.6 million for same period in 2015 . BioSpecifics Technologies Corp says co expects to initiate a clinical trial of CCH in uterine fibroids in second half of 2016 . Line results for its trial of cch in human lipoma in june of 2016 . BioSpecifics Technologies Corp. Reports first quarter 2016 financial results .Q1 earnings per share $0.39.  Full Article